Name : Human HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein
Product Source :
Recombinant Human HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein is expressed from E.coli with His tag and Avi tag at the C-Terminus. It contains Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and VVVGAGGVGK peptide.[Accession | AAV53343.1(HLA-A*11:01)&P61769(B2M)&VVVGAGGVGK]
Molecular Weight :
The protein has a predicted MW of 35.36 kDa (HLA-A*11:01) and 11.9 kDa (B2M) same as Tris-Bis PAGE result.
Endotoxin Level :
Less than 1EU per μg by the LAL method.
Purity :
> 95% as determined by Tris-Bis PAGE> 95% as determined by HPLC
Formulation :
Supplied as 0.22 μm filtered solution in PBS (pH 7.4).
Reconstitution :
Storage and Stability :
Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Product Concentration :
Tris-Bis PAGE Human HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer on Tris-Bis PAGE under reduced condition. The purity is greater than 95%. SEC-HPLC The purity of Human HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer is greater than 95% as determined by SEC-HPLC.
Background :
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.
Synonyms :
MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD
References & Citations :
(1) Wu HZ, Xiao JQ, Xiao SS, Cheng Y. KRAS: A Promising Therapeutic Target for Cancer Treatment. Curr Top Med Chem. 2019;19(23):2081-2097. doi: 10.2174/1568026619666190905164144. PMID: 31486755.
Related category websites: https://www.medchemexpress.com/recombinant-proteins.html
Popular product recommendations:
EGF Protein
IFN-gamma Protein
Popular categories:
Decay Accelerating Factor (DAF)
IL-17 Receptor